Publications by authors named "Michela Mangia"
Background And Aims: Telemonitoring is increasingly used in the management of IBD patients. We investigated the agreement between patients and physicians on scores of disease activity and burden.
Methods: Consecutive outpatients at one IBD clinic were recruited between February and December 2021.
Article Synopsis
- Adalimumab (ADA) is a monoclonal antibody used to treat inflammatory bowel diseases like Crohn's disease (CD), and vitamin D (VD) plays a role in drug metabolism and transport.
- This study aimed to assess how genetic variations in VD-related genes (single-nucleotide polymorphisms or SNPs) could predict clinical remission in CD patients treated with ADA over 3 and 12 months.
- Results showed that specific lifestyle and genetic factors influenced remission outcomes, highlighting the need for further research to validate these findings.
Inflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC), can be associated with several extra-intestinal manifestations requiring a multidisciplinary management both in terms of work-up and therapy. Oral lesions are common in patients with IBD, with a prevalence ranging from 5% to 50%. These can represent an oral location of IBD as well as a side-effect of drugs used to treat the intestinal disease.
View Article and Find Full Text PDFBackground: Nonalcoholic fatty liver disease (NAFLD) is common in inflammatory bowel diseases (IBD). Herein, NAFLD prevalence and risk factors in a large IBD cohort were evaluated and compared to that of a non-IBD sample.
Methods: Crohn's disease/ulcerative colitis outpatients referred to IBD service of our Gastroenterology Unit were enrolled.